Botox Alternative “Reloxin” is Subject of New Study

A medical study on the safety of the wrinkle relaxer ‘Reloxin’ was just published in the March-April issue of Archives of Facial Plastic Surgery.  The drug was evaluated for use on moderate to severe forehead wrinkles (or glabeller lines), and the results sound optimistic.

The FDA has not yet given its approval for Reloxin to be sold in the U.S., but spokespersons from Medicis Pharmaceutical say clearance is expected late this year.  Reloxin has the potential to become a real competitor for Botox in the U.S. cosmetic surgery market – a market which allowed Allergan Inc. to net $1.3 billion in revenue last year with Botox.

One California dermatologist who participated in the study commented to Bloomberg news, saying “the side effects are the same as Botox” and “many of our patients liked it even better.”

The composition of both Reloxin and Botox is very similar; they each contain a particular ‘botulinum toxin’ that has been proven to relax the muscles that cause wrinkles in the face.

Reloxin has actually been sold overseas under the name ‘Dysport’ for about 15 years, but Botox has still managed to claim over 80 percent of the worldwide market for the neurotoxin.  One market analyst speculates that “Reloxin may be priced 15 percent lower than Botox” which could allow it to take a significant share of that market.